ESR1 and breast cancer: We endorse the reflex testing for postmenopausal patients < 70 years with ER+/HER2- breast cancers, both node-negative and 1-3 node positive and the following tumor characteristics: T1c-2, Grade 2-3 and at least one of Ki67 21-40% or PgR < 20%.